Microneutralization Assay Titres Correlate with Protection against Seasonal Influenza H1N1 and H3N2 in Children
Open accessAbstract
Although the microneutralization (MN) assay has been shown to be more sensitive than the hemagglutination inhibition (HAI) assay for the measurement of humoral immunity against influenza viruses, further evidence relating MN titres to protective efficacy against infection is needed. Serum antibodies against seasonal H1N1 and H3N2 influenza were measured in children and adolescents (n = 656) by MN and hemagglutination inhibition (HAI) assays. Compared to HAI, the MN assay is more sensitive in detecting serum antibodies and estimates of protective effectiveness against PCR-confirmed infection were higher for both subtypes. Given our findings, the MN assay warrants further consideration as a formal tool for the routine evaluation of vaccine-induced antibody responses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Measurement of serum neutralizing activity has been shown to be a mechanistic correlate of protection for other respiratory viruses, such as influenza and respiratory syncytial virus, and is generally accepted as a functional biomarker of the in vivo humoral response.
“Though correlates of protection from SARS-CoV-2 infection have not yet been determined, measurement of serum neutralizing activity has been shown to be a mechanistic correlate of protection for other respiratory viruses, such as influenza14 and respiratory syncytial virus,15 and is generally accepted as a functional biomarker of the in vivo humoral response.16”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [14]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredThe BNT162b2 vaccine encodes the full-length trimerised S protein of SARS-CoV-2 and is formulated in lipid nanoparticles.
“The BNT162b2 vaccine encodes the full-length trimerised S protein of SARS CoV-2 and is formulated in lipid nanoparticles for delivery to cells12.”
From Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies (2021) · cites this paper as [12]
Participants showed similar neutralising activity against wild type pseudovirus as in the phase I/II study.
“Participants showed similar neutralising activity against wild type pseudovirus as in the phase I/II study12.”
From Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903810 · Cited by 3,047 · see citing works
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715 · see citing works
Singh, R. P., Kurz, J., & Boiteau, G. (1996) · Journal of Virological Methods · doi:10.1016/0166-0934(96)02096-4 · Cited by 2,554 · see citing works
Effect of Influenza Vaccination of Children on Infection Rates in Hutterite Communities
Loeb, M. B., Russell, M. L., Moss, L., Fonseca, K., Fox, J. D., Earn, D. J. D., Aoki, F. Y., Horsman, G. B., Caeseele, P. G. V., Chokani, K., et al. (2010) · JAMA · doi:10.1001/jama.2010.250 · Cited by 387 · see citing works
Self-citationBLACK, S. B., Nicolay, U., Vesikari, T., Knuf, M., Giudice, G. D., Cioppa, G. D., Tsai, T. F., Clemens, R. L., & Rappuoli, R. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182367662 · Cited by 333 · see citing works
Tsang, T. K., Cauchemez, S., Perera, R. A. P. M., Freeman, G., Fang, V. J., Ip, D., Leung, G. M., Peiris, M. J. S., & Cowling, B. J. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu186 · Cited by 129 · see citing works
Hardelid, P., Andrews, N., Höschler, K., Stanford, E., Baguelin, M., Waight, P., Zambon, M. C. F. A., & Miller, E. (2010) · Health Technology Assessment · doi:10.3310/hta14550-03 · Cited by 103 · see citing works
Ng, S., Fang, V. J., Ip, D., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit372 · Cited by 90 · see citing works
Grund, S., Adams, O., Wählisch, S., & Schweiger, B. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.11.024 · Cited by 63 · see citing works
Hsu, J. P., Zhao, X., Chen, M. I.-C., et al. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-414 · Cited by 59 · see citing works
Correlates of vaccine protection from influenza and its complications
McCullers, J. A., & Huber, V. C. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.18214 · Cited by 55 · see citing works
Serum 25-Hydroxyvitamin D Level and Influenza Vaccine Immunogenicity in Children and Adolescents
Science, M. E., Maguire, J. L., Russell, M. L., Smieja, M., Walter, S. D., & Loeb, M. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083553 · Cited by 22 · see citing works
Self-citationYam, K. K., Gupta, J., Brewer, A., et al. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00619-12 · Cited by 18 · see citing works
Self-citationCheng, L.-W., Huang, S.-W., Huang, L., et al. (2012) · Journal of Virological Methods · doi:10.1016/j.jviromet.2012.03.004 · Cited by 17 · see citing works
Herrera, M. T., González, Y., Juárez, E., et al. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-544 · Cited by 15 · see citing works
Paccalin, M., Plouzeau, C., Bouche, G., et al. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540600749984 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729 · see citing works
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · see citing works
- Authors
- Verschoor, C. P., Singh, P., Russell, M. L., Bowdish, D. M. E., Brewer, A., Cyr, L., Ward, B. J., & Loeb, M.
- Affiliations
- Michael G. DeGroote Institute for Infectious Disease Research (CA)
- McMaster University (CA)
- University of Calgary (CA)
- McGill University Health Centre (CA)
- Corresponding author
- Loeb, Mark
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-24
- Volume
- 10
- Issue
- 6
- Pages
- e0131531
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4479562
- OpenAlex
- W1960083897
- Cited by
- 99
- References
- 16
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 11 · 2023: 2 · 2022: 2 · 2021: 12 · 2020: 12 · 2019: 8 · 2018: 8 · 2017: 11 · 2016: 5 · 2015: 2
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-09-22)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion, cc-by)
- eScholarship@McGill (McGill) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- McGill University
- McMaster University
- Public Health Agency of Canada
- Public Health Agency
- Canadian Institutes of Health Research (88113_1)
- National Institute of Allergy and Infectious Diseases (#1 U01 AI 76208-01A1, U01AI076208)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- microneutralization, hemagglutination inhibition test, H1N1 influenza, influenza H3N2, seasonal influenza, humoral immunity, vaccine-induced antibody response, children and adolescents, assay sensitivity
- MeSH terms
- Adolescent, Alberta, Antibodies, Viral, Antibody Formation, Child, Child, Preschool, Hemagglutination Inhibition Tests, Humans, Influenza, Human, Influenza Vaccines, Manitoba, Neutralization Tests, Prospective Studies, Polymerase Chain Reaction, Hemagglutinin Glycoproteins, Influenza Virus, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
